过去一年中添加的文章，按日期排序
[HTML] amegroups.org

[HTML][HTML] Improving patient selection through tumor genomic recharacterization to overcome resistance to targeted therapy: commentary on the final analysis of the …

F Pecci, B Ricciuti, JV Alessi, A De Giglio… - AME Clinical Trials …, 2023 - actr.amegroups.org
212 天前 - … kinase inhibitors (TKIs) have been developed, revamping the therapeutic scenario
of advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations (1,2). …
相关文章 所有 5 个版本

OSI-774

W Zhanga, LL Siub, MJ Moorea, EX Chenb - shp099inhibitor.com
348 天前 - … best supportive care demonstrated a survival benefit using this agent in patients
with advanced non-small-cell lung cancer after prior platinum-based and docetaxel therapies […
相关文章